Print   



For immediate release

23 March 2009

ALIZYME PLC

BOARD APPOINTMENTS AND RESIGNATION

Cambridge UK, 23 March 2009: Alizyme plc (LSE:AZM) announces the appointments of Dr Roger Lloyd and Mr Richard de Souza as Non-Executive Directors with effect from 1 April 2009 and the resignation of Mr William Edge as a Non-Executive Director with effect from 1 April 2009. 

Dr Lloyd, aged 60, is a senior biotechnology and healthcare industry professional with over 33 years' experience working for ICI, Zeneca and AstraZeneca. Originally trained as a biochemist, his business development experience has been extensive. Numerous international transactions have included corporate acquisitions, product and technology licensing, joint ventures, divestments, corporate merger and demerger. His international experience has included living and working in the United States and Germany, and having territorial responsibilities for Europe, Japan, Korea, Mexico and the Middle East. He recently retired as Executive Director, Global Licensing in AstraZeneca plc and is currently a non-executive director of Epistem Holdings plc. Dr Lloyd will join the Board with effect from 1 April 2009. There are no other disclosures relating to Dr Lloyd under Listing Rule LR 9.6.13. 

Mr de Souza, aged 56, is a pharmacist who started his career at SmithKline Beecham in manufacturing before moving through business development and marketing roles into general management. Through his earlier career, he has been Managing Director, then Regional Director, living in six countries worldwide and has served as the Area Director with overall responsibility in Marketing and Business Development for Europe, USA and international markets during his twenty-two years with SmithKline Beecham. He served as Chairman Europe for SmithKline Beecham and then President Europe and International for Warner Lambert. Latterly at Shire, he was Director International, responsible for Pharmaceuticals outside the US and Biologicals and Diagnostics globally. In 2004 he set up Archimedes Pharma Ltd, a European specialty pharmaceutical company, where he is Chairman and CEO. Mr de Souza will join the Board with effect from 1 April 2009. There are no other disclosures relating to Mr de Souza under Listing Rule LR 9.6.13.  

Mr  Edge, who has served as a Non-Executive Director since 1998, will retire from the Board with effect from 1 April 2009.

Sir Brian Richards (Chairman) commented:

'I am delighted to welcome Roger Lloyd and Richard de Souza to the Board. I believe they will provide invaluable advice and guidance in enabling Alizyme to pursue its strategy and achieve its objectives of becoming a profitable, self-sustaining biopharmaceutical product development company.

I would like to thank Bill for his many years of support and advice to Alizyme.'

For further information, please contact:

ALIZYME PLC  Tim McCarthy, Chief Executive Officer	Tel: + 44 (0) 1223 896000
BUCHANAN COMMUNICATIONS Lisa Baderoon Rebecca Skye Dietrich	Tel: + 44 (0) 20 7466 5000  Tel: + 44 (0) 7721 413496

Further information on Alizyme can be found on the Company's website: www.alizyme.com

ENDBOAPUUBPWUPBGBP